|Bid||1.9300 x 900|
|Ask||1.9400 x 1800|
|Day's Range||1.9300 - 1.9900|
|52 Week Range||1.4300 - 5.1500|
|Beta (3Y Monthly)||1.11|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Is Correvio Pharma Corp. (NASDAQ:CORV) a good equity to bet on right now? We like to check what the smart money thinks first before doing extensive research. Although there have been several high profile failed hedge fund picks, the consensus picks among hedge fund investors have historically outperformed the market after adjusting for known risk […]
On a per-share basis, the Vancouver, British Columbia-based company said it had a loss of 23 cents. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by ...
Loss per share was ($0.20) as SG&A expenses grew reflecting an increase in the sales force. Newsflow during the third quarter continued to be very positive for Brinavess, and management has guided to a 2Q:19 resubmission to the FDA. Trevyent is now in the hands of United Therapeutics (UTHR) following their acquisition of SteadyMed.
2018 has been an exciting year for Correvio Pharma Corp. (CORV) (CORV.TO), with several transformative events taking place. Brinavess continues to achieve milestones with the recent conclusion of the pre-NDA meeting, confirmation of the timeline for FDA action and receipt of an opinion regarding an extension of the patent term. The most exciting news for the year was the FDA’s announcement regarding the resubmission of Brinavess and the scheduling of a pre-NDA meeting.
Correvio Pharma Corp. (CORV) has had an exciting year for Brinavess so far in 2018. While it received EMA regulatory approval in 2010, it was not given the go ahead in the United States and has been on hold with the FDA ever since. Despite the hold, things have begun to turn in favor of Brinavess on several fronts.
Junior miners turned lower in sympathy with declining gold and silver contracts, while small biotech and medical diagnostic stocks picked up the slack, underpinned by sector funds probing new highs. September has a mixed reputation when it comes to small speculative plays, suggesting that traders focus their attention on penny stocks exhibiting the highest relative strength while avoiding falling knives that may face tax selling pressure in the fourth quarter. Low-priced energy stocks look like wild cards in this equation, with crude oil coming off lows while rising Middle East tensions add to sector buying power.